297 related articles for article (PubMed ID: 24156030)
1. Curcumin improves the therapeutic efficacy of Listeria(at)-Mage-b vaccine in correlation with improved T-cell responses in blood of a triple-negative breast cancer model 4T1.
Singh M; Ramos I; Asafu-Adjei D; Quispe-Tintaya W; Chandra D; Jahangir A; Zang X; Aggarwal BB; Gravekamp C
Cancer Med; 2013 Aug; 2(4):571-82. PubMed ID: 24156030
[TBL] [Abstract][Full Text] [Related]
2. Mage-b vaccine delivered by recombinant Listeria monocytogenes is highly effective against breast cancer metastases.
Kim SH; Castro F; Gonzalez D; Maciag PC; Paterson Y; Gravekamp C
Br J Cancer; 2008 Sep; 99(5):741-9. PubMed ID: 18728665
[TBL] [Abstract][Full Text] [Related]
3. High efficacy of a Listeria-based vaccine against metastatic breast cancer reveals a dual mode of action.
Kim SH; Castro F; Paterson Y; Gravekamp C
Cancer Res; 2009 Jul; 69(14):5860-6. PubMed ID: 19584282
[TBL] [Abstract][Full Text] [Related]
4. Direct incorporation of the NKT-cell activator α-galactosylceramide into a recombinant Listeria monocytogenes improves breast cancer vaccine efficacy.
Singh M; Quispe-Tintaya W; Chandra D; Jahangir A; Venkataswamy MM; Ng TW; Sharma-Kharkwal S; Carreño LJ; Porcelli SA; Gravekamp C
Br J Cancer; 2014 Nov; 111(10):1945-54. PubMed ID: 25314062
[TBL] [Abstract][Full Text] [Related]
5. STING ligand c-di-GMP improves cancer vaccination against metastatic breast cancer.
Chandra D; Quispe-Tintaya W; Jahangir A; Asafu-Adjei D; Ramos I; Sintim HO; Zhou J; Hayakawa Y; Karaolis DK; Gravekamp C
Cancer Immunol Res; 2014 Sep; 2(9):901-10. PubMed ID: 24913717
[TBL] [Abstract][Full Text] [Related]
6. Myeloid-derived suppressor cells have a central role in attenuated Listeria monocytogenes-based immunotherapy against metastatic breast cancer in young and old mice.
Chandra D; Jahangir A; Quispe-Tintaya W; Einstein MH; Gravekamp C
Br J Cancer; 2013 Jun; 108(11):2281-90. PubMed ID: 23640395
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic targeting with DABIL-4 depletes myeloid suppressor cells in 4T1 triple-negative breast cancer model.
Parveen S; Siddharth S; Cheung LS; Kumar A; Shen J; Murphy JR; Sharma D; Bishai WR
Mol Oncol; 2021 May; 15(5):1330-1344. PubMed ID: 33682324
[TBL] [Abstract][Full Text] [Related]
8. Myeloid-derived suppressor cell depletion therapy targets IL-17A-expressing mammary carcinomas.
Dawod B; Liu J; Gebremeskel S; Yan C; Sappong A; Johnston B; Hoskin DW; Marshall JS; Wang J
Sci Rep; 2020 Aug; 10(1):13343. PubMed ID: 32770025
[TBL] [Abstract][Full Text] [Related]
9. Immunization against HIF-1α Inhibits the Growth of Basal Mammary Tumors and Targets Mammary Stem Cells
Cecil DL; Slota M; O'Meara MM; Curtis BC; Gad E; Dang Y; Herendeen D; Rastetter L; Disis ML
Clin Cancer Res; 2017 Jul; 23(13):3396-3404. PubMed ID: 28039264
[No Abstract] [Full Text] [Related]
10. Apoptotic Resistance of Metastatic Tumor Cells in Triple Negative Breast Cancer: Roles of Death Receptor-5.
Kamalabadi-Farahani M; H Najafabadi MR; Jabbarpour Z
Asian Pac J Cancer Prev; 2019 Jun; 20(6):1743-1748. PubMed ID: 31244295
[TBL] [Abstract][Full Text] [Related]
11. In vivo responses to vaccination with Mage-b, GM-CSF and thioglycollate in a highly metastatic mouse breast tumor model, 4T1.
Gravekamp C; Leal B; Denny A; Bahar R; Lampkin S; Castro F; Kim SH; Moore D; Reddick R
Cancer Immunol Immunother; 2008 Jul; 57(7):1067-77. PubMed ID: 18094967
[TBL] [Abstract][Full Text] [Related]
12. Anti-inflammatory signaling by mammary tumor cells mediates prometastatic macrophage polarization in an innovative intraductal mouse model for triple-negative breast cancer.
Steenbrugge J; Breyne K; Demeyere K; De Wever O; Sanders NN; Van Den Broeck W; Colpaert C; Vermeulen P; Van Laere S; Meyer E
J Exp Clin Cancer Res; 2018 Aug; 37(1):191. PubMed ID: 30111338
[TBL] [Abstract][Full Text] [Related]
13. Vaccination with Mage-b DNA induces CD8 T-cell responses at young but not old age in mice with metastatic breast cancer.
Castro F; Leal B; Denny A; Bahar R; Lampkin S; Reddick R; Lu S; Gravekamp C
Br J Cancer; 2009 Oct; 101(8):1329-37. PubMed ID: 19826426
[TBL] [Abstract][Full Text] [Related]
14. Tumor membrane-based vaccine immunotherapy in combination with anti-CTLA-4 antibody confers protection against immune checkpoint resistant murine triple-negative breast cancer.
Pack CD; Bommireddy R; Munoz LE; Patel JM; Bozeman EN; Dey P; Radhakrishnan V; Vartabedian VF; Venkat K; Ramachandiran S; Reddy SJC; Selvaraj P
Hum Vaccin Immunother; 2020 Dec; 16(12):3184-3193. PubMed ID: 32530786
[TBL] [Abstract][Full Text] [Related]
15. Syntenin1/MDA-9 (SDCBP) induces immune evasion in triple-negative breast cancer by upregulating PD-L1.
Liu J; Yang Y; Wang H; Wang B; Zhao K; Jiang W; Bai W; Liu J; Yin J
Breast Cancer Res Treat; 2018 Sep; 171(2):345-357. PubMed ID: 29845474
[TBL] [Abstract][Full Text] [Related]
16. Protective immunity to Listeria monocytogenes elicited by immunization with heat-killed Listeria and IL-12. Potential mechanism of IL-12 adjuvanticity.
Miller MA; Skeen MJ; Ziegler HK
Ann N Y Acad Sci; 1996 Oct; 797():207-27. PubMed ID: 8993364
[TBL] [Abstract][Full Text] [Related]
17. Prevention of metastases with a Mage-b DNA vaccine in a mouse breast tumor model: potential for breast cancer therapy.
Sypniewska RK; Hoflack L; Tarango M; Gauntt S; Leal BZ; Reddick RL; Gravekamp C
Breast Cancer Res Treat; 2005 May; 91(1):19-28. PubMed ID: 15868428
[TBL] [Abstract][Full Text] [Related]
18. Cooperative Immune-Mediated Mechanisms of the HDAC Inhibitor Entinostat, an IL15 Superagonist, and a Cancer Vaccine Effectively Synergize as a Novel Cancer Therapy.
Hicks KC; Knudson KM; Lee KL; Hamilton DH; Hodge JW; Figg WD; Ordentlich P; Jones FR; Rabizadeh S; Soon-Shiong P; Schlom J; Gameiro SR
Clin Cancer Res; 2020 Feb; 26(3):704-716. PubMed ID: 31645354
[TBL] [Abstract][Full Text] [Related]
19. Combination Immunotherapy of MUC1 mRNA Nano-vaccine and CTLA-4 Blockade Effectively Inhibits Growth of Triple Negative Breast Cancer.
Liu L; Wang Y; Miao L; Liu Q; Musetti S; Li J; Huang L
Mol Ther; 2018 Jan; 26(1):45-55. PubMed ID: 29258739
[TBL] [Abstract][Full Text] [Related]
20. B19-VLPs as an effective delivery system for tumour antigens to induce humoral and cellular immune responses against triple negative breast cancer.
Jiménez-Chávez ÁJ; Nava-García BK; Bustos-Jaimes I; Moreno-Fierros L
Immunol Lett; 2021 Nov; 239():77-87. PubMed ID: 34508790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
